Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR Inhibitors in Neuroendocrine Tumor Therapy | Zendy

Corinne Bousquet | Zendy; Charline Lasfargues | Zendy; Mounira Chalabi | Zendy; Siham Moatassim Billah | Zendy; Christiane Susini | Zendy; Delphine Vezzosi | Zendy; Philippe Caron | Zendy; Stéphane Pyronnet | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR Inhibitors in Neuroendocrine Tumor Therapy

Author(s) -

Corinne Bousquet,

Charline Lasfargues,

Mounira Chalabi,

Siham Moatassim Billah,

Christiane Susini,

Delphine Vezzosi,

Philippe Caron,

Stéphane Pyronnet

Publication year - 2011

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-2088

Subject(s) - pasireotide , everolimus , somatostatin receptor , somatostatin , lanreotide , neuroendocrine tumors , pi3k/akt/mtor pathway , octreotide , pharmacology , cancer research , medicine , sirolimus , signal transduction , biology , acromegaly , microbiology and biotechnology , hormone , growth hormone

Among the innovative molecules used to manage neuroendocrine tumors, there is growing interest in combining the somatostatin analogs octreotide or pasireotide (SOM230) and everolimus (RAD001), an inhibitor that targets the protein kinase mammalian target of rapamycin (mTOR).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research